Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the “Trial”) of Proxalutamide’s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board (“IRB”) of Brazil .
| SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Suzhou Kintor Pharma Limited (HKEX: 9939) is pleased to announce that the clinical trial (the “Trial”) of Proxalutamide’s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board (“IRB”) of Brazil. The trial was accepted for accelerated review. We have received support from the Brazilian government in terms of medical resources allocation and expect to start with the patients recruitment over the coming weekend. The Trial is a double-blinded, randomized and multi-center investigational study of Proxalutamide’s treatment for hospitalized COVID-19 male and female patients of 18 years old or above. Approximately 588 patients (294 male and 294 female) who meet the eligibility criteria will be enrolled within 48 hours of admission to hospital. The estimated time from screening to the end of the Trial for each patient will be 28 days. The Trial will have two cohorts of men and women and two arms of Proxalutamide Arm and Control Arm, respectively. The patients will be randomized to each arm at a ratio of 1:1. In the Proxalutamide Arm, patients will be orally administered Proxalutamide 300mg once daily (QD) for 14 days. In the Control Arm, patients will be orally administered placebo once daily (QD) for 14 days. Each arm will also receive standard of care as determined by the principal investigator at the site. The primary endpoint of the trial is the treatment efficacy of Proxalutamide arm relative to the Control arm as assessed by the WHO COVID-19 ordinal scale on day 14. Dr. Tong Youzhi, the founder, chairman and CEO of Kintor Pharmaceutical, commented, “Based on the results that Proxalutamide could alleviate symptoms and has reduced hospitalization risk of 100% for male COVID-19 outpatients and 90% for female COVID-19 outpatients, respectively, we collaborated with our investigator and quickly initiated the clinical study of Proxalutamide for the treatment of hospitalized COVID-19 male and female patients. This Clinical Trial has received strong support from the Brazilian government and was granted with the accelerated review. We are actively initiating MRCT phase III registrational trials, so as to bring an effective treatment therapy to COVID-19 patients over the world.” About Kintor Pharmaceutical Limited Founded in 2009, Kintor Pharmaceuticals aims to become a leading enterprise in the R&D and commercialization of “best-in-class” and “first-in-class” innovative therapies. The Company initially focused on androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as COVID-19, prostate cancer, breast cancer, liver cancer ,hair loss and acne. Kintor Pharmaceuticals has prospectively developed a diversified product pipeline that includes small molecule innovative drugs, bio-innovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as PD-L1/TGF-β dual-targeting antibody, AR-Degrader and c-Myc inhibitors that are undergoing preclinical research. Globally, the Company has more than 60 issued patents or under review, many of which are listed as the “Major New Drugs Discovery” in National 12th and 13th Five-Year Plans. On 22 May 2020, the Company was officially listed on the Hong Kong Stock Exchange with the stock ticker 9939.HK. Please visit http://www.kintor.com.cn for more information.
SOURCE Kintor Pharmaceutical Limited | ||
Company Codes: HongKong:9939 |
View original content:
